{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:57:46Z","timestamp":1794023866938,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s13555-022-00774-2","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T18:02:32Z","timestamp":1659290552000},"page":"1729-1751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Systematic Literature Review of Economic Evaluations and Cost Studies of the Treatment of Psoriasis, Atopic Dermatitis, and Chronic Urticaria"],"prefix":"10.1007","volume":"12","author":[{"given":"Atsuyuki","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-7231","authenticated-orcid":false,"given":"Akira","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yonemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LoPresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Murofushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,31]]},"reference":[{"key":"774_CR1","unstructured":"HSS. Inflammatory disorders. 2020. Available from: https:\/\/www.hss.edu\/condition-list_inflammatory-disorders.asp. Accessed 27 Oct 2020."},{"issue":"8","key":"774_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2020.1573","volume":"156","author":"MR Laughter","year":"2020","unstructured":"Laughter MR, Maymone MBC, Karimkhani C, Rundle C, Hu S, Wolfe S, et al. The burden of skin and subcutaneous diseases in the United States from 1990 to 2017. JAMA Dermatol. 2020;156(8):1\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1573.","journal-title":"JAMA Dermatol"},{"key":"774_CR3","unstructured":"Mayoclinic. Atopic dermatitis (eczema). 2020. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/atopic-dermatitis-eczema\/diagnosis-treatment\/drc-20353279. Accessed 27 Oct 2020."},{"key":"774_CR4","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1111\/jdv.16329","volume":"34","author":"C Pascal","year":"2020","unstructured":"Pascal C, Maucort-Boulch D, Gilibert S, et al. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. J Eur Acad Dermatol Venereol. 2020;34:2339\u201345.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"774_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/1346-8138.14502","volume":"45","author":"A Itakura","year":"2018","unstructured":"Itakura A, Tani Y, Kaneko N, et al. Impact of chronic urticaria on quality of life and work in Japan: results of a real-world study. J Dermatol. 2018;45:963\u201370.","journal-title":"J Dermatol"},{"key":"774_CR6","unstructured":"Wait M, Rath L. Newer drug treatments for psoriatic arthritis. 2020. Available from: https:\/\/www.arthritis.org\/diseases\/more-about\/newer-drug-treatments-for-psoriatic-arthritis. Accessed 27 Oct 2020."},{"issue":"Suppl 1","key":"774_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13555-016-0167-9","volume":"7","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths CEM, van de Kerkhof P, Czarnecka-Operacz M. Psoriasis and atopic dermatitis. Dermatol Ther. 2017;7(Suppl 1):31\u201341. https:\/\/doi.org\/10.1007\/s13555-016-0167-9.","journal-title":"Dermatol Ther"},{"key":"774_CR8","doi-asserted-by":"publisher","unstructured":"Godse KV. Chronic urticaria and treatment options. Indian J Dermatol. 2009;54(4):310\u20132. https:\/\/doi.org\/10.4103\/0019-5154.57603. Available from: https:\/\/www.e-ijd.org\/article.asp?issn=0019-5154;year=2009;volume=54;issue=4;spage=310;epage=312;aulast=Godse.","DOI":"10.4103\/0019-5154.57603"},{"key":"774_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskander IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590.","journal-title":"BMJ"},{"issue":"Supplement 23","key":"774_CR10","first-page":"S115","volume":"8","author":"C Avena-Woods","year":"2017","unstructured":"Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;8(Supplement 23):S115\u201323.","journal-title":"Am J Manag Care"},{"key":"774_CR11","unstructured":"Medscape. What is the prevalence of urticaria (hives) in the US? 2020. Available at: https:\/\/www.medscape.com\/answers\/762917-36206\/what-is-the-prevalence-of-urticaria-hives-in-the-us. Accessed 27 Oct 2020."},{"issue":"5","key":"774_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/bjd.16248","volume":"178","author":"A Svensoon","year":"2018","unstructured":"Svensoon A, Ofenloch RF, Bruze M, Naldi L, Cazzaniga S, Elsner P, et al. Prevalence of skin disease in a population-based sample of adults from five European countries. Br J Dermatol. 2018;178(5):1111\u20138. https:\/\/doi.org\/10.1111\/bjd.16248.","journal-title":"Br J Dermatol"},{"issue":"4","key":"774_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1346-8138.2011.01209.x","volume":"38","author":"M Furue","year":"2011","unstructured":"Furue M, Yamazaki S, Jimbow K, Tsuchida T, Amagai M, Tanaka T, et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol. 2011;38(4):310\u201320. https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01209.x.","journal-title":"J Dermatol"},{"issue":"11","key":"774_CR14","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"K Ronholt","year":"2017","unstructured":"Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"774_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1080\/21645515.2019.1582403","volume":"15","author":"Q Thibodeaux","year":"2019","unstructured":"Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15(9):2129\u201339.","journal-title":"Hum Vaccin Immunother"},{"key":"774_CR16","first-page":"25","volume":"9","author":"A Cooke","year":"2015","unstructured":"Cooke A, Bulkhi A, Casale TB. Role of biologics in intractable urticaria. Biologics. 2015;9:25\u201333.","journal-title":"Biologics"},{"issue":"6","key":"774_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","volume":"151","author":"EA Brezinski","year":"2015","unstructured":"Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651\u20138.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"774_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","volume":"107","author":"R Burgos-Pol","year":"2016","unstructured":"Burgos-Pol R, Mart\u00ednez-Sesmero JM, Ventura-Cerd\u00e1 JM, El\u00edas I, Caloto MT, Casado MA. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016;107(7):577\u201390.","journal-title":"Actas Dermosifiliogr"},{"key":"774_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-319-64804-0_8","volume":"1027","author":"AS Adamson","year":"2017","unstructured":"Adamson AS. The economics burden of atopic dermatitis. Adv Exp Med Biol. 2017;1027:79\u201392. https:\/\/doi.org\/10.1007\/978-3-319-64804-0_8.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"774_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li W, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Investig Dermatol. 2017;137(1):26\u201330. https:\/\/doi.org\/10.1016\/j.jid.2016.07.012.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"774_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/jdv.17203","volume":"35","author":"N Mohr","year":"2021","unstructured":"Mohr N, Naatz M, Zeervi L, Langenbruch A, Bieber T, Werfel T, et al. Cost-of-illness of atopic dermatitis in Germany: data from dermatology routine care. J Eur Acad Dermatol Venereol. 2021;35(6):1346\u201356.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"774_CR22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2340\/00015555-3257","volume":"99","author":"C Theodosiou","year":"2019","unstructured":"Theodosiou C, Montgomery S, Metsini S, Dalgard FJ, Svensson A, Kobyletzki LB. Burden of atopic dermatitis in Swedish adults: a population-based study. Acta Derm Venereol. 2019;99(11):964\u201370.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"774_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/archdermatol.2007","volume":"144","author":"LK Delong","year":"2008","unstructured":"Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144(1):35\u20139. https:\/\/doi.org\/10.1001\/archdermatol.2007.","journal-title":"Arch Dermatol"},{"key":"774_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/CEOR.S98848","volume":"8","author":"M Al-Ahmad","year":"2016","unstructured":"Al-Ahmad M, Alowayesh MS, Norman VC. Economic burden of refractory chronic spontaneous urticaria on Kuwait\u2019s health system. Clinicoecon Outcomes Res. 2016;8:163\u20139.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"774_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40273-020-00986-4","volume":"39","author":"A Yuasa","year":"2021","unstructured":"Yuasa A, Yonemoto M, LoPresti M, Ikeda S. Use of productivity loss\/gain in cost-effectiveness analyses for drugs: a systematic review. Pharmacoeconomics. 2021;39(1):81\u201397. https:\/\/doi.org\/10.1007\/s40273-020-00986-4.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"774_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189765","volume":"13","author":"C Kromer","year":"2018","unstructured":"Kromer C, Celis D, Sonntag D, Peitsch WKM, Reinert R, Augustin M. Biologicals and small molecules in psoriasis: a systematic review of economic evaluations. PLoS ONE. 2018;13(1): e0189765. https:\/\/doi.org\/10.1371\/journal.pone.0189765.","journal-title":"PLoS ONE"},{"issue":"2","key":"774_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14737167.2019.1549491","volume":"19","author":"M Gutknecth","year":"2019","unstructured":"Gutknecth M, Reinert R, Augustin M. Review of health economic analyses in atopic dermatitis: how diverse is the literature? Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):127\u201345. https:\/\/doi.org\/10.1080\/14737167.2019.1549491.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"774_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/bjd.17696","volume":"181","author":"TH Sach","year":"2019","unstructured":"Sach TH, McManus E, Levell NJ. Understanding economic evidence for the prevention and treatment of atopic eczema. Br J Dermatol. 2019;181(4):707\u201316. https:\/\/doi.org\/10.1111\/bjd.17696.","journal-title":"Br J Dermatol"},{"issue":"7","key":"774_CR29","doi-asserted-by":"publisher","first-page":"A562","DOI":"10.1016\/j.jval.2012.08.2017","volume":"15","author":"MS Woods","year":"2012","unstructured":"Woods MS, Zimovetz E, Beard S, Balp MM. PRS18 systematic review of economic evaluations, utility estimates, resource utilisation, and costs in chronic idiopathic urticaria. Value Health. 2012;15(7):A562. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2017.","journal-title":"Value Health."},{"key":"774_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.543290","volume":"7","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Xiao Y, Chen X, Li J, Shen M. A systematic review and meta-analysis of health utility estimates in chronic spontaneous urticaria. Front Med (Lausanne). 2020;7: 543290. https:\/\/doi.org\/10.3389\/fmed.2020.543290.","journal-title":"Front Med (Lausanne)."},{"key":"774_CR31","unstructured":"Centre for Reviews and Dissemination (CRD). Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. York: Centre for Reviews and Dissemination (CRD), University of York; 2009."},{"key":"774_CR32","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.0. London: Cochrane; 2019. https:\/\/training.cochrane.org\/handbook. Accessed 3 June 2020.","DOI":"10.1002\/9781119536604"},{"key":"774_CR33","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1136\/bmj.b2535.","DOI":"10.1136\/bmj.b2535"},{"key":"774_CR34","doi-asserted-by":"publisher","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100.","DOI":"10.1371\/journal.pmed.1000100"},{"issue":"7052","key":"774_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275\u201383. https:\/\/doi.org\/10.1136\/bmj.313.7052.275.","journal-title":"BMJ"},{"issue":"3","key":"774_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jval.2018.10.006","volume":"22","author":"RD Watts","year":"2019","unstructured":"Watts RD, Li IW. Use of checklists in reviews of health economic evaluations, 2010 to 2018. Value Health. 2019;22(3):377\u201382. https:\/\/doi.org\/10.1016\/j.jval.2018.10.006.","journal-title":"Value Health."},{"key":"774_CR37","doi-asserted-by":"publisher","unstructured":"Min C, Xue M, Haotian F, Jialian L, Lingli Z. An overview of the characteristics and quality assessment criteria in systematic review of pharmacoeconomics. PLoS ONE. 2021;16(2):e0246080. https:\/\/doi.org\/10.1371\/journal.pone.0246080.","DOI":"10.1371\/journal.pone.0246080"},{"key":"774_CR38","doi-asserted-by":"publisher","unstructured":"Burton HE, Mitchell SA, Watt M. A systematic literature review of economic evaluations of antibiotic treatments for Clostridium difficile infection. Pharmacoeconomics. 2017;35(11):1123\u201340. https:\/\/doi.org\/10.1007\/s40273-017-0540-2.","DOI":"10.1007\/s40273-017-0540-2"},{"issue":"3","key":"774_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173600","volume":"12","author":"SF Hope","year":"2017","unstructured":"Hope SF, Webster J, Trieu K, Pillay A, Ieremia M, Bell C, et al. A systematic review of economic evaluations of population-based sodium reduction interventions. PLoS ONE. 2017;12(3): e0173600. https:\/\/doi.org\/10.1371\/journal.pone.0173600.","journal-title":"PLoS ONE"},{"key":"774_CR40","doi-asserted-by":"publisher","unstructured":"Mordin M, Parrish W, Masaquel C, et al. Intra-articular hyaluronic acid for osteoarthritis of the knee in the United States: a systematic review of economic evaluations. Clin Med Insights Arthritis Musculoskelet Disord. 2021;14:11795441211047284. https:\/\/doi.org\/10.1177\/11795441211047284.","DOI":"10.1177\/11795441211047284"},{"key":"774_CR41","doi-asserted-by":"publisher","unstructured":"Woods T, Tesfay F, Speck P, Kaambwa B. Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: systematic review. PLoS ONE. 2020;15(4):e0232395. https:\/\/doi.org\/10.1371\/journal.pone.0232395.","DOI":"10.1371\/journal.pone.0232395"},{"issue":"1","key":"774_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jval.2019.07.003","volume":"23","author":"C Gorry","year":"2020","unstructured":"Gorry C, McCullagh L, Barry M. Economic evaluation of systemic treatments for advanced melanoma: a systematic review. Value Health. 2020;23(1):52\u201360. https:\/\/doi.org\/10.1016\/j.jval.2019.07.003.","journal-title":"Value Health."},{"issue":"5","key":"774_CR43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jval.2020.02.005","volume":"23","author":"S Niyomsri","year":"2020","unstructured":"Niyomsri S, Duarte RV, Eldabe S, Fiore G, Kopell BH, McNicol E, et al. A systematic review of economic evaluations reporting the cost-effectiveness of spinal cord stimulation. Value Health. 2020;23(5):656\u201365. https:\/\/doi.org\/10.1016\/j.jval.2020.02.005.","journal-title":"Value Health."},{"issue":"7","key":"774_CR44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2165\/11539970-000000000-00000","volume":"29","author":"M Krol","year":"2011","unstructured":"Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics. 2011;29(7):601\u201319. https:\/\/doi.org\/10.2165\/11539970-000000000-00000.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"774_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/hec.4730030606","volume":"3","author":"MA Koopmanschap","year":"1994","unstructured":"Koopmanschap MA, Rutten FF. The impact of indirect costs on outcomes of health care programs. Health Econ. 1994;3(6):385\u201393. https:\/\/doi.org\/10.1002\/hec.4730030606.","journal-title":"Health Econ"},{"key":"774_CR46","doi-asserted-by":"publisher","unstructured":"Johannesson M, Jonsson B, J\u00f6nsson L, Kobelt G, Zethraeus N. Why should economic evaluations of medical innovations have a societal perspective? SSRN Electron J. 2009;51. https:\/\/doi.org\/10.2139\/ssrn.2640123. Available from: https:\/\/www.ohe.org\/publications\/why-should-economic-evaluations-medical-innovations-have-societal-perspective.","DOI":"10.2139\/ssrn.2640123"},{"issue":"4","key":"774_CR47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10198-009-0173-2","volume":"10","author":"B J\u00f6nsson","year":"2009","unstructured":"J\u00f6nsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357\u20139. https:\/\/doi.org\/10.1007\/s10198-009-0173-2.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"774_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1017\/S0266462300161100","volume":"16","author":"PW Stone","year":"2000","unstructured":"Stone PW, Chapman RH, Sandberg EA, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses: variations in the literature. Int J Technol Assess Health Care. 2000;16(1):111\u201324.","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"774_CR49","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. https:\/\/doi.org\/10.3390\/ijms21051690.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"774_CR50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4029.","journal-title":"JAMA Dermatol"},{"key":"774_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00266-6","author":"T Bieber","year":"2021","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2021. https:\/\/doi.org\/10.1038\/s41573-021-00266-6.","journal-title":"Nat Rev Drug Discov"},{"key":"774_CR52","unstructured":"American College of Clinical Pharmacology. FDA approves Dupixent (dupilumab) for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 2017. Available from: https:\/\/www.accp1.org\/accp1\/5publications_and_news\/fda_approves_dupixent__dupilumab_.aspx. Accessed 27 Dec 2021."},{"key":"774_CR53","unstructured":"Chugai Pharmaceutical. Maruho obtained regulatory approval for Mitchga, the first antibody targeting IL-31 for itching associated with atopic dermatitis. Chugai Pharmaceutical press release. 2021. Available from: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20220328160001_908.html. Accessed 15 Apr 2022."},{"key":"774_CR54","unstructured":"Leo Pharma. LEO Pharma announces FDA approval of Adbry\u2122 (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis. Leo Pharma press release. 2021. Available from: https:\/\/financialpost.com\/pmn\/press-releases-pmn\/business-wire-news-releases-pmn\/leo-pharma-announces-fda-approval-of-adbry-tralokinumab-as-the-first-and-only-treatment-specifically-targeting-il-13-for-adults-with-moderate-to-severe-atopic-dermatitis. Accessed 27 Dec 2021."},{"issue":"11","key":"774_CR55","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/healthcare9111575","volume":"9","author":"G Radi","year":"2021","unstructured":"Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A. Baricitinib: the first Jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients. Healthcare (Basel). 2021;9(11):1575. https:\/\/doi.org\/10.3390\/healthcare9111575.","journal-title":"Healthcare (Basel)"},{"key":"774_CR56","unstructured":"Cision PR Newswire. US FDA Approves RINVOQ\u00ae (upadacitinib) to treat adults and children 12 years and older with refractory, moderate to severe atopic dermatitis. 2022. Available from: https:\/\/www.prnewswire.com\/news-releases\/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis-301461377.html. Accessed 15 Apr 2022."},{"key":"774_CR57","unstructured":"Gavidia M. FDA approves abrocitinib for adults with moderate to severe atopic dermatitis. Am J Manag Care. 2022. Available from: https:\/\/www.ajmc.com\/view\/fda-approves-abrocitinib-for-adults-with-moderate-to-severe-atopic-dermatitis. Accessed 15 Apr 2022."},{"issue":"10","key":"774_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078152","volume":"8","author":"SIB Steinke","year":"2013","unstructured":"Steinke SIB, Peitsch WK, Ludwig A, Goebeler M. Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy. PLoS ONE. 2013;8(10): e78152.","journal-title":"PLoS ONE"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00774-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T03:27:42Z","timestamp":1659929262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00774-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,31]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00774-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,31]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}